PUBLICATIONS.
An overview of our publications at a glance.
OUR PUBLICATIONS
Here we report on publications by our members as well as our collaborative studies within the NOA.
OUR PUBLICATIONS
2022
Focal cavity radiotherapy after neurosurgical resection of brain metastases: sparing neurotoxicity without compromising locoregional control.
2022
Focal cavity radiotherapy after neurosurgical resection of brain metastases: sparing neurotoxicity without compromising locoregional control.
Klaus-Henning Kahl, Ehab Shiban, Susanne Gutser, Christoph J Maurer, Björn Sommer, Heiko Müller, Ina Konietzko, Ute Grossert, Ansgar Berlis, Tilman Janzen, Georg Stüben
Strahlenther Onkol . 2022 Sep 23. doi: 10.1007/s00066-022-02003-3
2021
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
2021
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W.
Nature. 2021 Apr;592(7854):463-468
2020
Intraoperative radiotherapy with low energy X-rays after neurosurgical resection of brain metastases.
2020
Intraoperative radiotherapy with low energy X-rays after neurosurgical resection of brain metastases.
Klaus-Henning Kahl, Nikolaos Balagiannis, Michael Höck, Sabine Schill, Zoha Roushan, Ehab Shiban, Heiko Müller, Ute Grossert, Ina Konietzko, Maximilian-Niklas Bonk, Christoph Maurer, Ansgar Berlis, Volkmar Heidecke, Tilman Janzen, Georg Stüben
Augsburg University Medical Center experience – Strahlentherapie und Onkologie
2020
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study.
2020
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study.
Dirven L, Luerding R, Beier D, Bumes E, Reinert C, Seidel C, Bonsanto MM, Bremer M, Rieken S, Combs SE, Herrlinger U, Seliger C, Kuntze H, Mayer-Steinacker R, Dieing A, Bartels C, Schnell O, Weyerbrock A, Seidel S, Grauer O, Nadji-Ohl M, Paulsen F, Weller M, Wick W, Hau P.
J Neurooncol. 2020 May;148(1):117-130
2020
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promotor-methylated malignant astrocytoma.
2020
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promotor-methylated malignant astrocytoma.
Wick A,, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, Felsberg J, Weyerbrock A, Papsdorf K, Steinbach JP, Sabel M, Vesper J, Debus J, Meixensberger J, Ketter R, Hertler C, Mayer-Steinacker R, Weisang S, Bölting H, Reuss D, Reifenberger G, Sahm F, von Deimling A, Wick W; NOA-08 Study Group of the Neurooncology Working Group (NOA) of the German Cancer Society
Neuro Oncol. 2020;22: 1162 – 1172
2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trail.
2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trail.
Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldliks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabei G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U.
J Neurooncol. 2019;144: 501 – 509
2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomised, open-label, phase 3 trial.
2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F et al.
Lancet 2019;393: 678 – 688
2019
N²M² (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
2019
N²M² (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M.
Neuro Oncol 2019;21: 95 – 105
2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Gold-brunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N
Lancet Oncol. 2019;20: 1444 – 1453
2018
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promotor-hypermethylation – the NCT Neuro Master Match (N²M²) pilot study.
2018
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promotor-hypermethylation – the NCT Neuro Master Match (N²M²) pilot study.
Pfaff E, Kessler T, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW, Wicke W, Sahm F.
Neuro Oncol 2018;20: 826 – 837